Increasing levels of circulating PCSK9 are associated with higher levels of circulating Lp(a), driven by small Lp(a) particles (≤24 Kringle IV type 2 repeats) – consistent with a mechanistic hypothesis that the PCSK9/LDL receptor axis may be involved in the metabolism of small but not large Lp(a) particles.
Educational Partners and Supporters
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
(Founding Partner)